Regulatory-Aligned Environmental Risk Assessment Support

Regulatory ERA Pharmaceutical Compounds CRO India
Agrochemical & Pharmaceutical ERA

Regulatory-Aligned Environmental Risk Assessment for Pharmaceutical Compounds

Environmental Risk Assessment (ERA) for pharmaceutical compounds is not simply a scientific exercise — it is a regulatory requirement embedded in the marketing authorisation process for medicinal products in many jurisdictions, including the European Union.

Regulatory bodies such as the European Medicines Agency (EMA) have established specific guidance on how ERA should be conducted, structured and documented for pharmaceutical submissions. Meeting these requirements demands a thorough understanding of the ERA framework, the applicable test guidelines, the data requirements at each assessment tier and the scientific standards expected of the supporting studies.

Accuprec Research Labs supports regulatory-aligned ERA through an integrated approach encompassing environmental fate and exposure assessment, ecotoxicological hazard characterization, PEC/PNEC evaluation, PBT/vPvB assessment and regulatory dossier support.


The Framework

The ERA Framework

The ERA framework for pharmaceutical compounds follows a tiered, stepwise approach. The assessment begins with a Phase I screening evaluation based on predicted environmental concentrations and progresses to Phase II studies involving environmental fate, exposure characterization and ecotoxicological testing when trigger values are exceeded or when the compound has properties of potential environmental concern.

This tiered structure is designed to focus scientific resources where they are most needed, allowing straightforward cases to be resolved early while ensuring that more complex or potentially concerning substances receive thorough evaluation.

The ERA framework addresses three primary areas of environmental assessment:

  • Environmental fate and exposure — understanding where the compound goes and in what concentrations
  • Ecotoxicological hazard — understanding what effects the compound may have on environmental organisms
  • Risk characterization — bringing exposure and hazard together through PEC/PNEC assessment and risk quotient evaluation

Environmental Fate & Exposure

Environmental fate and exposure assessment characterizes the behaviour of a pharmaceutical compound in environmental systems and estimates the concentrations to which organisms may be exposed.

Fate studies relevant to regulatory ERA include hydrolysis, photolysis, ready biodegradability, water/sediment transformation, soil transformation and adsorption/desorption. These studies generate data that characterizes persistence, compartment distribution and the formation of transformation products.

Exposure assessment involves the estimation of Predicted Environmental Concentrations (PECs) in relevant compartments — surface water, groundwater, sediment and soil — based on the fate data and applicable regulatory exposure models. The resulting PEC values form the exposure side of the risk characterization equation.

Regulatory guidance, including EMA’s guideline on ERA for medicinal products (EMEA/CHMP/SWP/4447/00), provides specific requirements for the fate endpoints that must be addressed and the models to be used for PEC calculation at each assessment tier.


Ecotoxicological Hazard Characterization

Ecotoxicological hazard assessment evaluates the potential effects of a pharmaceutical compound on environmental organisms. The ERA framework requires testing across multiple trophic levels to ensure that the ecological effects of a substance are assessed comprehensively.

For the aquatic compartment, standard ecotoxicological testing typically covers:

  • Algae — representing primary producers in aquatic ecosystems
  • Aquatic invertebrates (e.g. Daphnia) — representing primary consumers
  • Fish — representing higher trophic levels in aquatic systems

Where the environmental fate assessment indicates potential for significant sediment or terrestrial exposure, additional ecotoxicological testing may be required, covering sediment-dwelling organisms, soil invertebrates, plants and terrestrial organisms.

The ecotoxicological endpoints generated from these studies — including No Observed Effect Concentrations (NOECs), EC50 values and LC50 values — provide the data needed for PNEC derivation and risk characterization.


PEC/PNEC Assessment

PEC/PNEC assessment brings together the exposure and hazard components of the ERA. The Predicted Environmental Concentration (PEC) derived from fate and exposure assessment is compared against the Predicted No-Effect Concentration (PNEC) derived from ecotoxicological data.

The resulting Risk Quotient (RQ = PEC/PNEC) provides a quantitative basis for evaluating the relationship between predicted environmental exposure and the concentration associated with no expected ecological effects.

Risk Quotient = PEC / PNEC

Within the regulatory framework, an RQ below 1 generally indicates that the predicted exposure does not exceed the no-effect concentration, while an RQ of 1 or above triggers further assessment or risk management consideration. However, the interpretation of RQ values must account for data quality, uncertainty factors applied in PNEC derivation and the specific regulatory context.

PEC/PNEC assessment must be conducted for each relevant environmental compartment — aquatic, sediment and terrestrial — based on the environmental fate profile of the compound.


PBT & vPvB Assessment

In addition to the PEC/PNEC risk characterization, the ERA framework requires an assessment of whether a pharmaceutical compound meets criteria for classification as Persistent, Bioaccumulative and Toxic (PBT) or very Persistent and very Bioaccumulative (vPvB).

PBT and vPvB assessment involves evaluating the compound against defined criteria for:

  • Persistence (P/vP) — based on degradation half-lives in water, sediment and soil
  • Bioaccumulation (B/vB) — based on the bioconcentration factor (BCF) or octanol-water partition coefficient (log Kow)
  • Toxicity (T) — based on ecotoxicological endpoints and, where relevant, human health data

If a substance meets PBT or vPvB criteria, additional risk management measures may be required, as conventional risk characterization approaches may not fully address the long-term environmental implications of persistent and bioaccumulative substances.


Risk Characterization

Risk characterization integrates all of the ERA components to provide an overall assessment of the environmental risk posed by a pharmaceutical compound.

A complete risk characterization considers:

  • PEC/PNEC ratios for all relevant environmental compartments
  • PBT/vPvB assessment outcomes
  • Transformation product profiles and their potential environmental significance
  • Data quality and uncertainty in both exposure and hazard assessments
  • The overall weight of evidence across all available environmental information

The conclusions of risk characterization inform the environmental risk sections of regulatory dossiers and, where applicable, may support the development of risk management or mitigation proposals.


Regulatory Dossier Support

The ERA must be documented and presented in a format that meets the requirements of the applicable regulatory authority. For EMA submissions, the environmental risk assessment is presented as part of Module 1.6 of the Common Technical Document (CTD), with supporting scientific data referenced in the appropriate modules.

A well-structured ERA dossier clearly presents the assessment approach, the data used, the conclusions at each tier and the overall risk characterization. It should address all relevant environmental compartments, demonstrate that the applicable regulatory guidance has been followed and provide justification where scientific judgment or non-standard approaches have been applied.

Accuprec Research Labs supports organizations in developing ERA documentation that is scientifically rigorous, clearly structured and aligned with the expectations of applicable regulatory frameworks.


EMA / OECD / GLP Context

Regulatory ERA for pharmaceutical compounds is conducted within a well-defined scientific and regulatory context:

EMA

EMA Guidance

The EMA guideline on ERA for medicinal products (EMEA/CHMP/SWP/4447/00) provides the primary regulatory framework for ERA in EU marketing authorisation applications. It defines the Phase I and Phase II assessment requirements, trigger values and documentation expectations.

OECD

OECD Test Guidelines

Environmental fate and ecotoxicological studies for ERA are conducted according to OECD Test Guidelines, which define standardized methodologies for each study type. Use of OECD guidelines supports regulatory acceptance of study data across jurisdictions.

GLP

GLP Compliance

Studies intended for regulatory submission are typically required to be conducted under Good Laboratory Practice (GLP). GLP provides a quality framework that ensures the integrity, reliability and traceability of study data, supporting regulatory confidence in the submitted findings.


Accuprec Research Labs: Regulatory ERA Support

Accuprec Research Labs provides end-to-end support for regulatory-aligned Environmental Risk Assessment for pharmaceutical compounds. Our integrated ERA capabilities cover the full scope of the assessment framework — from Phase I screening through Phase II environmental fate, ecotoxicological testing, PEC/PNEC assessment and regulatory dossier preparation.

We work within the EMA/OECD/GLP framework to ensure that the studies and assessments we support meet the scientific and documentary standards required for regulatory submissions. Our team combines expertise in environmental chemistry, ecotoxicology and regulatory science to deliver assessments that are scientifically robust and aligned with applicable guidance.

Whether your organization is preparing an initial ERA for a new active substance, addressing regulatory queries on an existing ERA, or seeking to update an assessment in line with current guidance, Accuprec Research Labs can provide the scientific and regulatory support you need.

Partner with Accuprec Research Labs Pvt. Ltd. for regulatory-aligned Environmental Risk Assessment support across the full ERA framework.


What do you think?
Leave a Reply

Your email address will not be published. Required fields are marked *

Insights

More Related Articles

Complete ERA: Phase I–V Framework for Pharmaceuticals

Environmental Fate & Transformation Products: Understanding Pharmaceutical Compounds in the Environment 

Meet Accuprec at MEDICA 2026 Düsseldorf